Lisa Curcio, MD
Surgical Oncology · Rhinebeck, NYNPI 1306846324
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,900 of the $2,894 with a category attached, or 65.6%. Davol Inc. accounts for 66.7% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $1,410 and has fallen 98.3% since, to $24 in 2025.
Across 18 payments — averaging $160.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$2K
- Stryker$474
- Endomagnetics Ltd$110
- Medtronic$87
- KCI USA, Inc.$73
- Leica Microsystems Inc.$45
- plus $176 from 8 others
What the payments were for
- Speaking & faculty fees$1,90066%
- Travel & lodging$50417%
- Food & beverage$49117%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 3 | $1,930 |
| Stryker | 2 | $474 |
| Endomagnetics Ltd | 1 | $110 |
| Medtronic | 1 | $87 |
| KCI USA, Inc. | 1 | $73 |
| Leica Microsystems Inc. | 2 | $45 |
| Puma Biotechnology, Inc. | 1 | $27 |
| Myriad Genetic Laboratories, Inc. | 1 | $26 |
| Merck | 1 | $26 |
| Dilon Technologies, Inc. | 1 | $24 |
| AbbVie | 1 | $24 |
| Amgen | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Tempus AI, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,894 in reported general payments places this provider in the 70th percentile of 173 surgical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgical oncology in Rhinebeck
- Sheldon FeldmanNew York$97K
- Kepal PatelNew York$94K
- Helen CappuccinoBuffalo$70K
- Jose Alberty OllerStaten Island$63K
- Megan WinnerMineola$51K
- George PlitasNew York$39K
- James ParkNew York$28K
- Anna WeissRochester$27K
- Michael LoweNew York$20K
- James NitzkorskiPoughkeepsie$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.